Alerta

リポタンパク質ＬＰ－Ｚを使用して肝疾患死亡率を予測する方法

Absstract of: CN113614540A

Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy and more specifically for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.

オリゴヌクレオチド製剤

Absstract of: WO2024255846A1

Provided herein are oligonucleotide formulations. In particular, it relates to formulations of oligonucleotide comprising oligonucleotide (such as ASO, siRNA, saRNA) and calcium, methods the preparation of the formulation, and use thereof. The oligonucleotide formulations have reduced in vivo acute toxicity (especially in central nervous system) and expanded in vivo safety window for the oligonucleotides especially the lipid conjugate, and thus having great application prospect.

SNCG蛋白在辅助诊断前列腺癌症中的应用

Absstract of: CN120427915A

The invention discloses application of SNCG protein in auxiliary diagnosis of prostate cancer, and relates to the technical field of biological medicine. The application way is as follows: the reagent for specifically detecting the expression of the SNCG protein in a biological sample is used for preparing a product for auxiliary diagnosis of the prostate cancer. Proteome analysis on urine proteins of a prostate cancer patient and a normal male shows that the concentration of the SNCG protein in the urine of the prostate cancer patient is obviously higher than that of the normal male group, and immunohistochemical analysis on archive wax blocks and surrounding normal prostate tissues of the prostate cancer patient shows that the SNCG protein can be applied to the prostate cancer patient. The SNCG protein has a certain expression rate in the prostate cancer, which indicates that the SNCG protein has a certain relationship with the occurrence and development of the prostate cancer, and can be used for assisting the diagnosis of the prostate cancer and the diagnosis of difficult cases so as to improve the diagnosis rate and the survival rate of patients.

一种检测阿尔茨海默病患者血浆中双标记物的生物传感器

Absstract of: CN122361826A

本发明公开了一种检测阿尔茨海默病患者血浆中双标记物的生物传感器，涉及生物传感器技术领域。所述生物传感器包括修饰ZnS/CdS/Bi2Se3复合物的电极、S1:C1:M三链体、S2:C2:M三链体和DNA分子系统。本发明的生物传感器以ZnS/CdS/Bi2Se3三元复合材料为传感基底，PtPd/CeO2异质结纳米酶为信号调控元件，结合适配体介导的特异性识别和支点触发的链置换反应，可以实现对阿尔茨海默病患者血浆中生物标志物β‑淀粉样蛋白1‑42和β‑淀粉样蛋白1‑40的同步双模式检测，适用于阿尔茨海默病的早期筛查和临床诊断，具有重要的应用价值。

一种提高p-tau 217项目化学发光水平的磁珠包被方法及应用

Absstract of: CN122361824A

0001 本发明涉及化学发光免疫分析技术领域，具体涉及一种提高p‑tau 217项目发光水平的磁珠包被方法及应用，本发明优化羧基磁珠包被p‑tau 217捕获抗体工艺，通过梯度调整EDC、NHS的投入比例，获得最适活化剂浓度以增强磁珠偶联活性，增大了抗体的偶联效率，进而提高了抗原样本与临床样本的信号值，对于p‑tau 217等低丰度蛋白的高灵敏检测的开发具有广阔的应用前景。

基于机器学习的表面增强拉曼光谱检测Tau蛋白方法、系统及装置

Absstract of: CN122361823A

0001 本发明公开基于机器学习的表面增强拉曼光谱检测Tau蛋白方法、系统及装置，该方法包括以下步骤：S1、构建具有最小初始拉曼信号的SERS信号探针；S2、将待测样本与所述SERS信号探针混合，利用拉曼光谱仪采集得到混合体系的SERS光谱；S3、对采集到的所述SERS光谱进行预处理，所述预处理包括依次进行的基线校正、特征峰识别及最小‑最大归一化处理，得到标准化的光谱数据；S4、将所述标准化的光谱数据输入至预先训练好的机器学习回归模型中，由所述机器学习回归模型基于输入的光谱特征自动输出待测样本中Tau蛋白的浓度值。本发明能够在保持高特异性的前提下，快速、准确、低检测限地定量检测磷酸化Tau蛋白，具有高临床转化潜力。

一种用于载脂蛋白E4检测的免疫层析检测试剂盒、制备方法及应用

Absstract of: CN122361827A

本发明公开了一种用于载脂蛋白E4检测的免疫层析检测试剂盒、制备方法及应用，包括检测卡和样本稀释液，检测卡包括试纸条，试纸条包括PVC底板、吸水纸、玻纤垫、硝酸纤维素膜，玻纤垫上负载有物理吸附用聚苯乙烯胶乳微球，物理吸附用聚苯乙烯胶乳微球的表面修饰有磺酰基或羟基，Zeta电位范围为‑15V~‑20V，且将物理吸附用聚苯乙烯胶乳微球均匀涂覆于载玻片上并烘干后与水珠形成的接触角大于90°；硝酸纤维素膜上负载有抗APOE4抗体、包被液及蛋白A，样本稀释液包括PBS、TWEEN‑20、Tetronic 1307、CHAPS。本发明省去了单克隆抗体1标记胶乳微球，降低了假阳性和试剂批间差，灵敏度更高。

铈掺杂高熵金属有机框架纳米酶及其制备方法、检测β-淀粉样蛋白1-42的方法

Absstract of: CN122356501A

0001 本发明公开了一种铈掺杂高熵金属有机框架纳米酶及其制备方法、检测β‑淀粉样蛋白1‑42的方法，属于纳米材料制备与分析化学交叉领域。其制备过程包括：将N,N‑二甲基甲酰胺、无水乙醇、超纯水、甘油和聚乙烯吡咯烷酮混合均匀；加入对苯二甲酸以及等摩尔量的可溶性三价铁盐、三价铈盐、二价钴盐、二价铜盐和二价镍盐；加入三乙胺在pH为9.0 9.5条件下搅拌反应并超声处理，然后将产物依次离心分离收集沉淀、洗涤和干燥，得到目标产品。本发明的纳米酶具有超宽的线性检测范围和良好的长期稳定性，适用于对目标分析物β‑淀粉样蛋白1‑42的快速、精准检测，为特定目标蛋白质的体外浓度监测与生化指标评估提供技术手段。

一种用于检测活性乙酰胆碱酯酶的生物传感器及其应用

Absstract of: CN122361564A

本发明属于生物传感技术领域，具体涉及一种用于检测活性乙酰胆碱酯酶的生物传感器及其应用。包括尖端具有纳米孔径的纳米管，用于产生电流阻断信号；环束DNA四面体载体，用于负载含活性乙酰胆碱酯酶的待检测溶液，环束DNA四面体载体为TDN1或TDN4，TDN1中的四条DNA单链的序列如SEQ ID NO.1至SEQ ID NO.4所示，TDN4中四条DNA单链的序列如SEQ ID NO.1、SEQ ID NO.3、SEQ ID NO.5和SEQ ID NO.6所示。本发明利用一种适配体两端锚定的闭环DNA四面体纳米结构，与活性AChE结合前后在纳米孔中产生电流信号差异，实现在单分子水平上对活性AChE的高灵敏和高选择性检测。

一种活性多肽、多肽衍生物及其应用

Absstract of: CN122356214A

0001 本发明属于生物医药技术领域，提供了一种具有 ATG8 蛋白结合活性的多肽，包括如下结构：X<1>‑X<2>‑X<3>‑X<4>‑X<5>‑X<6>‑X<7>；其中：X<1>、X<2>和X<3>独立地选自谷氨酸或不存在：X<4>选自色氨酸、苯丙氨酸或亮氨酸；X<5>为缬氨酸；X<6>选自亮氨酸、异亮氨酸或缬氨酸；X<7>选自缬氨酸、色氨酸、苯丙氨酸或酪氨酸。相较于现有的自噬抑制剂，该多肽在靶点选择、结合强度及作用机制方面具有如下更佳的药代潜力与开发灵活性：短序列不仅降低了合成成本，还为修饰留出了更灵活的空间，有望显著提升多肽的代谢稳定性和成药性潜力；可作为高效的ATG8靶向配体，广泛应用于生化探针构建、PPI竞争性抑制剂筛选及靶向递送系统的开发。

用于检测神经系统病症的氨基酸衍生物

Absstract of: WO2025117551A1

Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

检测核酸代谢物的方法及系统

Absstract of: CN120064427A

The invention discloses a method for detecting spatial distribution of brain nucleic acid hydrolysate based on mass spectrum imaging and an analysis system.The method comprises the steps of sample preparation, mass spectrum imaging and spatial quantitative analysis of nucleic acid hydrolysate, specifically, a spray needle capillary tube with the diameter being 10-30 micrometers is adopted, the angle between a spray needle and a sample glass slide is adjusted to be 55-57 degrees, the height is 35-36.5 mm, and the sample glass slide is placed in the sample capillary tube; the method comprises the following steps: uniformly spraying a spray solvent on the surface of a brain slice, scanning the whole sample to obtain mass spectrum imaging data, extracting the ion strength of target objects corresponding to different brain regions according to the monitored ion mass-to-charge ratio of the nucleic acid hydrolysate, and obtaining the spatial distribution of the nucleic acid hydrolysate in the different brain regions of the brain; the analysis system can extract the ion strength of the target object corresponding to the different brain regions according to the obtained brain mass spectrum and the monitored ion mass-to-charge ratio of the target object, the spatial distribution of the target object in the different brain regions is obtained, and spatial difference analysis among different groups is completed.

胞外囊泡组合物及其用途

Absstract of: WO2025081242A1

The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.

表征和利用药剂-凝聚物相互作用的方法

Absstract of: WO2020232416A1

Described herein are methods of characterizing agent incorporation into condensates, methods of reducing transcription of oncogenes associated with condensates, and methods of using peptides to inhibit nuclear receptor and cofactor binding in condensates.

识别ApoE4的兔源单克隆抗体

Absstract of: CN122356282A

0001 本发明提供了一种识别ApoE4的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK29，包括HZK29‑B0009、HZK29‑B0010和HZK29‑B0019。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE4。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。

一种抑制和/或清除β-淀粉样蛋白聚集的多肽及其应用

Absstract of: CN122356237A

0001 本发明涉及药物技术领域，尤其涉及一种抑制和/或清除β‑淀粉样蛋白聚集的多肽及其应用。本发明首先开发出了可从多靶点作用对阿尔茨海默病等β‑淀粉样蛋白聚集和沉积所引发的疾病发挥作用的功能性活性多肽ANI‑1，以对疾病起到有效的预防及其治疗的效果，本发明的多肽ANI‑1具有清除Aβ聚集、延缓β‑淀粉样蛋白毒性导致的行为衰退（抗瘫痪、促运动）、抑制β‑淀粉样蛋白沉积相关的神经性炎症并增强抗氧化防御的功能，具有更好的整体疗效和神经保护潜力，可为开发出多靶点的针对阿尔茨海默病等β‑淀粉样蛋白聚集和沉积所引发的疾病的多靶点药物提供新的思路。

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

Absstract of: US20260194540A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

SCFV ANTIBODY THAT SPECIFICALLY BINDS Aβ, AND USE THEREOF

Absstract of: WO2026144428A1

Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.

METHOD FOR DIAGNOSING EARLY AND CLASSIFYING STAGES OF ALZHEIMER'S DISEASE AND DETERMINING AMYLOID BETA ACCUMULATION IN BRAIN BY USING TAU PROTEIN-DERIVED PHOSPHORYLATED PEPTIDE

Absstract of: US20260194539A1

A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.

SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF

Absstract of: AU2024411321A1

The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.

BREATH COLLECTION TOOL

Absstract of: US20260191428A1

0000 A tool for collection of exhaled breath includes a microreactor for capturing and concentrating target compounds in a gaseous sample, such as exhaled breath. An airflow of exhaled breath enters the interior of the microreactor, then contacts the central area of the microreactor and is redirected radially outwards, passing through microfluidic channels formed between micropillars, and exits the microreactor through a plurality of vent holes at the periphery. The micropillars are coated with a capture material, such as a reactive compound capable of forming adducts with carbonyl-containing VOCs. The captured target compounds may then be eluted from the micropillars and analyzed for detection of disease states or other purposes.

METHOD AND REAGENTS FOR THE DETECTION OF AN AUTOANTIBODY

Absstract of: WO2026146226A1

The present invention relates to means and methods relevant to assessing the risk of developing and/or aiding in the diagnosis of an inflammatory vascular condition and/or a multimorbidity comprising a neurological autoimmune disease and an inflammatory vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having a neurological autoimmune disease. The present invention also relates to assessing the risk of developing and/or aiding in the diagnosis of a neurological autoimmune disease and/or a multimorbidity comprising a neurological autoimmune disease and a vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having an inflammatory vascular condition.

ANTIBODIES THAT BIND TO POST-TRANSLATIONALLY MODIFIED C9ORF72 ARGININE-RICH DIPEPTIDE REPEAT PROTEINS AND USES THEREOF

Absstract of: WO2026147818A1

Isolated monoclonal antibodies that bind to methylated dipeptide repeat proteins (DRPs), e.g., ADMe-GR and SDMe-GR, and related antibody-based compositions and molecules are disclosed. Also disclosed are diagnostic and therapeutic methods for using the antibodies.

ANTI-UNC5C ANTIBODIES AND USES THEREOF

Absstract of: AU2024398768A1

Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.

PROTEOMICS OF FITNESS

Nº publicación: US20260196299A1 09/07/2026

Applicant:

VANDERBILT UNIV [US]
NORTHWESTERN UNIV [US]
Vanderbilt University
Northwestern University

Absstract of: US20260196299A1

0000 Methods, systems, and kits are provided for assessing cardiorespiratory fitness and predicting cardiometabolic risk.